The grant provides modest non-dilutive capital to advance the cannabinoid analog pipeline, but at ~3% of market cap it is not a material near-term catalyst. Monitor for partnership announcements or progress on the NCT program, which the company notes is advancing toward commercialization.
Price Chart
Executive Summary
ExoZymes announced a $2,028,518 NIH SBIR Phase IIB grant to advance cannabinoid analogs for drug discovery. The two-year non-dilutive grant brings total non-dilutive funding to $19.7 million and validates the company's cell-free platform for rare cannabinoid production. While positive, the grant is modest relative to the $63M market cap and does not change the company's near-term financial outlook.
Key Facts
- Received $2,028,518 NIH SBIR Phase IIB grant for cannabinoid analog drug discovery
- Grant is non-dilutive, two-year term starting July 1, 2026
- Total non-dilutive funding awarded to eXoZymes now $19.7 million
- Grant supports three objectives: enzyme expression systems, analog expansion, and preclinical evaluation
Financial Impact
Non-dilutive grant of $2,028,518 over two years; total non-dilutive funding now $19.7 million
Risk Factors
- Grant funding is subject to continued progress and availability of appropriated funds
- Preclinical development may not lead to clinical candidates or commercial products
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-030205 |
| Exhibit: ex99-1.htm | 0001493152-26-030205 |
| Document: 0001493152-26-030205-index-headers.html | 0001493152-26-030205 |
| Document: 0001493152-26-030205-index.html | 0001493152-26-030205 |
| Document: 0001493152-26-030205.txt | 0001493152-26-030205 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 18d ago | 8-K | $5.25 | awaiting T+20 | — | $3.75 (−28.57%) |
Sep 28, 2026 29d ago | DEFA14A | $6.10 $3.80 | ▼ −37.70% | ▼ −38.42% | $3.75 (−38.52%) |
Sep 28, 2026 29d ago | DEF 14A | $6.10 $3.80 | ▼ −37.70% | ▼ −38.42% | $3.75 (−38.52%) |
Sep 18, 2026 5w ago | 8-K | $6.44 $4.09 | ▼ −36.44% | ▼ −36.65% | $3.75 (−41.72%) |
Jun 30, 2026 17w ago | 424B5 | $8.50 $4.40 | ▲ +48.24% | ▲ +46.05% | $3.75 (+55.88%) |
Jun 25, 2026 17w ago | 8-K | $8.03 $4.70 | ▼ −41.47% | ▼ −42.73% | $3.75 (−53.30%) |
Jun 17, 2026 18w ago | 8-K | $7.83 $6.22 | ▲ +20.56% | ▲ +21.09% | $3.75 (+52.11%) |
Jun 8, 2026 20w ago | 8-K | $8.62 $8.14 | ▲ +5.57% | ▲ +7.20% | $3.75 (+56.50%) |
Jun 8, 2026 20w ago | 424B5 | $8.62 $8.14 | ▲ +5.57% | ▲ +7.20% | $3.75 (+56.50%) |
Jun 4, 2026 20w ago | 424B5 | $9.35 $8.48 | ▲ +9.30% | ▲ +7.93% | $3.75 (+59.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers